Phase 4 N=158 IV Keppra in the Emergency Department for Prevention of Early Recurrent Seizures
Tonic-clonic Seizure
Primary: Number of Participants Who Experienced a Recurrent Seizure After Treatment. — 2; 3 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=24 Pharmacokinetics of the Brimonidine Tartrate Posterior Segment Delivery System in Patients Undergoing Pars Plana Vitrectomy
Vitrectomy
Primary: Highest Vitreous Humor Level of Brimonidine in the Study Eye — 137.0; 34.9 Nanogram/milliliter (ng/mL)
Phase 4 N=188 Concomitant Administration of FSH With HCG Improves Oocyte Maturation and Quality Double -Blinded Randomized Trial
Infertility
Primary: Mean Fertilization Proportion (2PN/Oocytes Collected) — 0.63; 0.55 proportion of oocytes fertilized
Phase 2 N=161 Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) in Acute Manic Episodes Associated With Bipolar I Disorder
Bipolar I Disorder
Primary: Change in the Young Mania Rating Scale (YMRS) Total Score at the End of the 3-week Treatment Period, in Relation to the Baseline. — -14.2; -12.5; -10.3 units on a scale
Phase 2 N=18 Pilot Study of Duloxetine in Psychological Resilience
Major Depressive Disorder
Primary: Change in Connor Davidson Resilience Scale (CD-RISC) From Baseline to 8 Weeks — 52.62 units on a scale — p=0.00365
Phase 3 N=294 An Efficacy and Safety Study of Paliperidone Extended-Release (ER) Tablets in Participants With Schizophrenia
Schizophrenia
Primary: Number of Participants With Treatment Response Based on Total PANSS Scale Score — 195 Participants
N/A N=72 Disability and Quality of Life in Patients With Lymphatic Filariasis in Rural Southern India
Lymphatic Filariasis
Primary: Dermatology Life Quality Index (DLQI) Domain Scores — 3; 0; 1; 0 units on a scale
Phase 3 N=386 Efficacy and Safety of a Herbal Medicinal Product (Dry Extract BNO 1016) in Patients With Acute Rhinosinusitis
Acute Rhinosinusitis
Primary: Major Symptom Score (MSS) Assessed by the Investigator — 2.38; 3.41 units on a scale
Phase 3 N=113 Growth Hormone in Neuroendocrine Dysfunction With Severe Fibromyalgia Syndrome
Fibromyalgia
Primary: Percentage of Participants With Less Than 11 Tender Points at Month 6 — 20; 22 Percentage of participants
Phase 3 N=259 Study of Pharmacotherapy of Psychotic Depression
Major Depressive Disorder With Psychotic Features
Primary: Remission of Depression Hamilton Depression Scale (Ham-D) and Psychosis Schedule for Affective Disorders in Schizophrenia - Delusional Item (SADS) During the Course of…
Phase 3 N=626 A Chronic Obstructive Pulmonary Disease (COPD) Trial Investigating Roflumilast on Safety and Effectiveness in China, Hong Kong and Singapore:
COPD
Primary: Change From Baseline in Pre-bronchodilator Forced Expiratory Volume in First Second (FEV1) — 0.049; -0.022 liters — p=<0.0001
Phase 4 N=19 Mycophenolate Mofetil Immunosuppression Without/With Reduced Dose Calcineurin Inhibitor Long After Liver Transplantation
Liver Disease
Primary: Number of Biopsy Proven Rejections at 12 Months — 0; 0 participants
Phase 4 N=3 Mobility Training Using a Bionic Knee Orthosis in Patients Chronic Post-Stroke: A Case Series
Stroke
Primary: Ambulation Speed — 0.60; 0.29; 0.83; 0.81 meters per second (m/s)
N/A N=47 Evaluation of a Radial Arterial Line's Effect on StO2 Monitoring
Oxygenation
Primary: Tissue Oxygen Saturation (StO2) Measurement on the Extremity With a Radial Arterial Line — 0.68 StO2 percent saturation — p=0.55
Phase 1 N=9 Intravenous N-acetylcysteine for the Treatment of Gaucher's Disease and Parkinson's Disease
Parkinson's Disease · Gaucher's Disease
Primary: Brain GSH — 55; 41; 34 percent increase from baseline